Losartan vs Ramipril

Both losartan and ramipril effectively lower blood pressure by 10–15 mmHg systolic at standard doses ^[1][2]. Ramipril has the most robust cardiovascular outcomes data of any ACE inhibitor, with the HOPE trial showing a 22% reduction in the combined endpoint of cardiovascular death, MI, and stroke in high-risk patients ^[2]. Losartan demonstrated renal protection in the RENAAL trial for type 2 diabetic nephropathy and stroke reduction in hypertensive patients with left ventricular hypertrophy in the LIFE trial ^[1]. The ONTARGET trial directly compared an ARB (telmisartan, not losartan) with ramipril and found them equivalent for cardiovascular outcomes, suggesting the classes provide similar cardioprotection ^[3]. Losartan uniquely lowers uric acid levels by 20–25%, which may benefit patients with gout ^[4]. Both drugs reduce proteinuria and preserve renal function in patients with CKD. Current ACC/AHA guidelines consider ACE inhibitors and ARBs equally appropriate first-line options for hypertension ^[3].

The primary side-effect difference drives most switching decisions. Ramipril causes dry cough in 5–20% of patients due to bradykinin accumulation — a class effect of all ACE inhibitors ^[2]. Losartan does not cause cough, making it the standard alternative for patients who develop ACE inhibitor cough ^[1]. Angioedema is rare with ramipril (0.1–0.7%) but can be life-threatening; ARBs have a much lower (but non-zero) angioedema risk ^[3]. Both drugs can cause hyperkalemia (1–3%), dizziness, and first-dose hypotension. Both are contraindicated in pregnancy. Losartan is generally better tolerated, with side-effect rates close to placebo in clinical trials ^[1]. Ramipril may cause more taste disturbances and skin rash than losartan. Combining an ACE inhibitor with an ARB (dual RAAS blockade) is NOT recommended — the ONTARGET trial showed that telmisartan plus ramipril increased adverse events without additional benefit ^[3]. Both require monitoring of potassium and renal function, particularly in patients with CKD or those taking potassium-sparing diuretics ^[4].

Both medications are available as inexpensive generics. Generic losartan 50 mg (30 tablets) costs $4–10 ^[1]. Generic ramipril 5 mg (30 capsules) costs $8–20, slightly more than losartan ^[2]. Both are covered by most insurance formularies at the lowest copay tier. When patients switch from ramipril to losartan due to cough, the cost difference is negligible. Brand-name Cozaar and Altace cost $150–300/month but are rarely prescribed.

Both are taken once daily. Losartan is available in 25, 50, and 100 mg tablets, with typical doses of 50–100 mg/day ^[1]. Ramipril comes in 1.25, 2.5, 5, and 10 mg capsules, with doses of 2.5–10 mg/day ^[2]. Neither requires food for administration. Ramipril capsules can be opened and sprinkled on applesauce. Both require periodic monitoring of serum potassium and creatinine (typically 1–2 weeks after initiation, then periodically) ^[3]. Losartan is also available in a fixed-dose combination with hydrochlorothiazide (Hyzaar), and ramipril can be combined with other antihypertensives. Neither drug requires special storage conditions.

Ramipril is often the initial choice for patients at high cardiovascular risk without heart failure (based on HOPE trial evidence), post-MI patients, and diabetic patients with microalbuminuria (MICRO-HOPE evidence) ^[2]. Losartan is preferred when patients develop ACE inhibitor cough (the most common reason for switching), when a patient has concurrent hyperuricemia or gout (uricosuric effect), for type 2 diabetic nephropathy (RENAAL trial evidence), or when angioedema has occurred with any ACE inhibitor ^[1][4]. For uncomplicated hypertension without specific comorbidities, guidelines consider both classes equally appropriate, and the choice often defaults to whichever the patient tolerates better ^[3]. Both provide comparable renal and cardiovascular protection through RAAS inhibition. Never combine an ACE inhibitor with an ARB. Consult your healthcare provider to determine which RAAS inhibitor best fits your clinical profile.